Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response

A Martens; R A Janssen; D T Sleijfer; A A Heijn; N H Mulder; T H The; L de Leij

doi:10.1038/bjc.1993.205

Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response

Br J Cancer. 1993 May;67(5):1118-21. doi: 10.1038/bjc.1993.205.

Authors

A Martens¹, R A Janssen, D T Sleijfer, A A Heijn, N H Mulder, T H The, L de Leij

Affiliation

¹ Department of Clinical Immunology, University Hospital Groningen, The Netherlands.

Abstract

Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Aged
CD8 Antigens / blood*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / immunology
Female
Humans
Injections, Subcutaneous
Interleukin-2 / therapeutic use*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / metabolism
Male
Middle Aged
Neoplasm Metastasis
Receptors, Interleukin-2 / metabolism
Recombinant Proteins / therapeutic use
Solubility
Time Factors

Substances

CD8 Antigens
Interleukin-2
Receptors, Interleukin-2
Recombinant Proteins